An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)

• Status: Recruiting
• Trial end date: 2022-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of this study is to evaluate the efficacy of psilocybin (25 mg) administered under supportive conditions to adult participants with severe TRD, in improving depressive symptoms.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sheppard Pratt Health System
• Collaborator: COMPASS Pathways
• Treatments: Psilocybin

Criteria

Inclusion Criteria:

• Diagnosis of at least moderate Major Depressive Disorder (MDD)

Exclusion Criteria:

• Comorbidities

Note for CA sites: Recruiting Local Veterans